PharmAthene Inc (PIP)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:PharmAthene Inc (PIP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013566
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PharmAthene Inc (PharmAthene) is a pharmaceutical company that develops and commercializes medical counter measures to biological and chemical weapons. The company’s products include recombinant protective antigen anthrax vaccine, human monoclonal antibody antitoxin and recombinant BChE bioscavenger. Its products are used for treatment of anthrax, and nerve agent poisoning. PharmAthene serves in markets of biodefense, US civilian, military, and non-US markets. The company collaborates with various pharma and research companies across the world. It markets its products through its distributors across the world. PharmaAthene is headquartered in Annapolis, Maryland, the US.

PharmAthene Inc (PIP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PharmAthene Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
PharmAthene Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
PharmAthene Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
PharmAthene Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
PharmAthene Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
PharmAthene Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
PharmAthene Enters into Agreement with National Institutes of Allergy and Infectious Diseases 10
Merger 11
Altimmune Merges with PharmAthene in Reverse Merger Transaction 11
Licensing Agreements 13
PharmAthene Enters Into Licensing Agreement With Percivia For PER.C6 Cell Line 13
Equity Offering 14
PharmAthene to Raise Additional USD30 Million in Public Offering of Shares 14
PharmAthene Completes Registered Direct Offering Of US$6.5 Million 15
PharmAthene Inc – Key Competitors 16
PharmAthene Inc – Key Employees 17
PharmAthene Inc – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Financial Announcements 19
May 03, 2017: PharmAthene Reports First Quarter 2017 Financial and Operational Results 19
Mar 14, 2017: PharmAthene Reports Year-End 2016 Financial and Operational Results 20
Nov 04, 2016: PharmAthene Reports Third Quarter 2016 Financial and Operational Results 21
Aug 04, 2016: PharmAthene Reports Second Quarter 2016 Financial and Operational Results 22
May 09, 2016: PharmAthene Reports First Quarter 2016 Financial and Operational Results 24
Mar 11, 2016: PharmAthene Reports Year-End 2015 Financial and Operational Results; Provides Update on Litigation with SIGA 25
Corporate Communications 26
Jul 08, 2016: PharmAthene Receives $20 Million Payment from SIGA to Extend Payment Deadline 26
Legal and Regulatory 27
Nov 16, 2016: PharmAthene Receives Final Payment from SIGA of $83.9 Million 27
Apr 13, 2016: PharmAthene Reports Court Approval of SIGA Reorganization Plan to Exit from Bankruptcy 28
Other Significant Developments 29
Sep 16, 2016: PharmAthene Announces Receipt of Payments from SIGA 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
PharmAthene Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
PharmAthene Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
PharmAthene Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
PharmAthene Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
PharmAthene Inc, Deals By Therapy Area, 2011 to YTD 2017 8
PharmAthene Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
PharmAthene Enters into Agreement with National Institutes of Allergy and Infectious Diseases 10
Altimmune Merges with PharmAthene in Reverse Merger Transaction 11
PharmAthene Enters Into Licensing Agreement With Percivia For PER.C6 Cell Line 13
PharmAthene to Raise Additional USD30 Million in Public Offering of Shares 14
PharmAthene Completes Registered Direct Offering Of US$6.5 Million 15
PharmAthene Inc, Key Competitors 16
PharmAthene Inc, Key Employees 17
PharmAthene Inc, Subsidiaries 18

★海外企業調査レポート[PharmAthene Inc (PIP)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kentucky Power Co:発電所・企業SWOT分析
    Kentucky Power Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees ( …
  • Alexion Pharmaceuticals Inc (ALXN):企業の財務・戦略的SWOT分析
    Alexion Pharmaceuticals Inc (ALXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Polo Resources Ltd (POL):石油・ガス:M&Aディール及び事業提携情報
    Summary Polo Resources Ltd (Polo Resources) is a natural resource and mine development investment company that evaluates, acquires, and develops substantial investments in companies and projects. The company also invests in exploration companies. It invests in the gold, oil and gas, coal, phosphate, …
  • Prospect Resources Limited:企業の戦略・SWOT・財務情報
    Prospect Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Prospect Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Lytron Inc.:企業の戦略・SWOT・財務情報
    Lytron Inc. - Strategy, SWOT and Corporate Finance Report Summary Lytron Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Kudelski SA (KUD):企業の財務・戦略的SWOT分析
    Kudelski SA (KUD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • The Co-operative Bank Plc:企業の戦略・SWOT・財務情報
    The Co-operative Bank Plc - Strategy, SWOT and Corporate Finance Report Summary The Co-operative Bank Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Denison Mines Corp. (DML):企業の財務・戦略的SWOT分析
    Denison Mines Corp. (DML) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • BioFactura Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary BioFactura Inc (Biofactura) is a manufacturer of biosimilars that discovers, develops and markets biodefense drugs and client selected novel drugs. The company provides contract services such as process development, stable cell lines, manufacturing, and others. Its stable cell line offers st …
  • Imprimis Pharmaceuticals Inc (IMMY):製薬・医療:M&Aディール及び事業提携情報
    Summary Imprimis Pharmaceuticals Inc (Imprimis), formerly Transdel Pharmaceuticals Inc., focuses on the development and commercialization of proprietary drug formulations in the therapeutic areas of urology and ophthalmology. The company by utilizing its SSP Technology develops injectable Dropless T …
  • Fortive Corporation:企業の戦略・SWOT・財務情報
    Fortive Corporation - Strategy, SWOT and Corporate Finance Report Summary Fortive Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Medicontur Medical Engineering Ltd:製品パイプライン分析
    Summary Medicontur Medical Engineering Ltd (Medicontur) is a developer and manufacturer of intraocular lenses. The company offers hydrophilic and hydrophobic model lenses including monofocal aspheric, toric, and standard monofocal aspheric lenses; preloaded capsular tension rings; PMMA implants; inj …
  • Bank of Maharashtra:企業の戦略・SWOT・財務情報
    Bank of Maharashtra - Strategy, SWOT and Corporate Finance Report Summary Bank of Maharashtra - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Mapletree Greater China Commercial Trust Management Ltd:企業の戦略・SWOT・財務情報
    Mapletree Greater China Commercial Trust Management Ltd - Strategy, SWOT and Corporate Finance Report Summary Mapletree Greater China Commercial Trust Management Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the compan …
  • Reliance Capital Ltd:企業のM&A・事業提携・投資動向
    Reliance Capital Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Reliance Capital Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • MediGene AG (MDG1):製薬・医療:M&Aディール及び事業提携情報
    Summary MediGene AG (MediGene) is a biotechnology company which develops drugs for the treatment of various types and stages of cancer with candidates in clinical and pre-clinical development. The company focuses on the development of personalized T-cell-based immunotherapies. Its core business deve …
  • Lantronix, Inc. (LTRX):企業の財務・戦略的SWOT分析
    Lantronix, Inc. (LTRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Deutsche Post AG:企業のM&A・事業提携・投資動向
    Deutsche Post AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Deutsche Post AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Ceres Power Holdings Plc (CWR):電力:M&Aディール及び事業提携情報
    Summary Ceres Power Holdings Plc (Ceres Power) is an alternative energy company that develops low cost and next generation fuel cell technologies. The company carries out developing steel cell a fuel cell technology that converts natural gas and hydrogen fuel directly into electrical power and heat …
  • 3E sanv:企業の戦略的SWOT分析
    3E sanv - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆